Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia

Unlike normal B cells, and similar to fat cells, chronic lymphocytic leukemia (CLL) cells aberrantly express lipoprotein lipase (LPL), which contributes to free fatty acids (FFAs) metabolism. Here we show that, in CLL cells, the B cell receptor (BCR) inhibitor ibrutinib reduced LPL mRNA and protein...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Leuk Lymphoma
Autors principals: Rozovski, Uri, Harris, David M., Li, Ping, Liu, Zhiming, Jain, Preetesh, Ferrajoli, Alessandra, Burger, Jan, Thompson, Phillip, Jain, Nitin, Wierda, William, Keating, Michael J., Estrov, Zeev
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6135679/
https://ncbi.nlm.nih.gov/pubmed/29465264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2018.1439167
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars